EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, Captor Therapeutics's enterprise value is zł281.15 Mil.
Captor Therapeutics's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 was zł13.20 Mil. Therefore, Captor Therapeutics's EV-to-Revenue for today is 21.30.
The historical rank and industry rank for Captor Therapeutics's EV-to-Revenue or its related term are showing as below:
WAR:CTX'
s EV-to-Revenue Range Over the Past 10 Years
Min: 24.72 Med: 98.15 Max: 1520.49
Current: 21.3
During the past 7 years, the highest EV-to-Revenue of Captor Therapeutics was 1520.49. The lowest was 24.72. And the median was 98.15.
WAR:CTX's EV-to-Revenue is ranked worse than 67.85% of 1039
companies
in the Biotechnology industry
Industry Median: 8.18
vs WAR:CTX: 21.30
The historical data trend for Captor Therapeutics's EV-to-Revenue can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Captor Therapeutics's EV-to-Revenue
For the Biotechnology subindustry, Captor Therapeutics's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Captor Therapeutics's EV-to-Revenue Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Captor Therapeutics's EV-to-Revenue distribution charts can be found below:
* The bar in red indicates where Captor Therapeutics's EV-to-Revenue falls into.
Captor Therapeutics's current Enterprise Value is zł281.15 Mil.
Captor Therapeutics's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was zł13.20 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Captor Therapeutics's share price for today is zł76.00.
Captor Therapeutics's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was zł2.60.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Captor Therapeutics EV-to-Revenue Related Terms
Thank you for viewing the detailed overview of Captor Therapeutics's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.
Captor Therapeutics (WAR:CTX) Business Description
Captor Therapeutics SA is a biopharmaceutical company. It is focused on development of protein degradation drugs for cancer and autoimmune diseases, which have limited or no known treatment options.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
WAR:CTX has been successfully added to your 